Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis
Open Access
- 28 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (11) , 3778-3786
Abstract
Background. ABO-incompatible living donor kidney transplantation based on specific conditioning has been successfully adopted by transplant centres worldwide. Excellent short-term results have been reported in small cohorts. However, long-term data and comparative analyses are still sparse. We report on the outcome of 40 consecutive ABO-incompatible living donor kidney transplant recipients and compare their clinical course to a control group of 43 ABO-compatible living donor transplant patients transplanted during the same time period. Methods. This is an observational single-centre analysis of 40 consecutive patients undergoing ABO-incompatible kidney grafting between April 2004 and April 2009, using a protocol of rituximab, antigen-specific immunoadsorption, intravenous immunoglobulin, basiliximab induction and oral triple immunosuppression with tacrolimus, mycophenolic acid and prednisone. Forty-three ABO-compatible kidney transplant recipients served as controls. The control group had also received basiliximab induction and an identical initial maintenance immunosuppression. The two groups were observed for an average of 39 and 19 months, respectively. Results. There was a significantly higher incidence of lymphoceles requiring surgical revisions in the ABO-incompatible group. However, this surgical complication did not affect patient or graft survival. Mean serum creatinine, estimated glomerular filtration rate and proteinuria did not differ between the two groups. Furthermore, ABO-incompatible and ABO-compatible patients had the same incidence of humoral and cellular rejections. Despite a more aggressive induction therapy, no differences in infectious or malignant complications were observed. Conclusions. ABO-incompatible living donor kidney transplantation utilizing a combination of rituximab and antigen-specific immunoadsorption yielded results identical to ABO-compatible transplantation despite a significantly higher number of human leukocyte antigen mismatches.Keywords
This publication has 17 references indexed in Scilit:
- Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant PatientsAmerican Journal of Transplantation, 2009
- ABO Incompatible Renal Transplantation: A Paradigm Ready for Broad ImplementationTransplantation, 2009
- ABO-Incompatible Kidney Transplantation Using Antigen-Specific Immunoadsorption and RituximabTransplantation, 2008
- Banff 07 Classification of Renal Allograft Pathology: Updates and Future DirectionsAmerican Journal of Transplantation, 2008
- Evaluation of Two Different Preconditioning Regimens for ABO-Incompatible Living Kidney Donor Transplantation2008
- Implementation of a Protocol for ABO-Incompatible Kidney Transplantation – A Three-Center Experience With 60 Consecutive TransplantationsTransplantation, 2007
- ABO‐incompatible kidney transplantation—Proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titersJournal of Clinical Apheresis, 2007
- Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in JapanAmerican Journal of Transplantation, 2004
- Plasma exchange conditioning for ABO‐incompatible renal transplantationJournal of Clinical Apheresis, 2004
- Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximabTransplantation, 2003